Fitzgerald Industries International, Inc. DBI Blocking Peptide 33R-6477

Description
A synthetic peptide for use as a blocking control in assays to test for specificity of DBI antibody, catalog no. 70R-2557 Background: DBI is diazepam binding inhibitor. The protein that is regulated by hormones and is involved in lipid metabolism and the displacement of beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors located in brain synapses. DBI is conserved from yeast to mammals, with the most highly conserved domain consisting of seven contiguous residues that constitute the hydrophobic binding site for medium- and long-chain acyl-Coenzyme A esters. Diazepam binding inhibitor is also known to mediate the feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin, in addition to its role as a mediator in corticotropin-depend ent adrenal steroidogenesis.
Description
A synthetic peptide for use as a blocking control in assays to test for specificity of DBI antibody, catalog no. 70R-2557 Background: DBI is diazepam binding inhibitor. The protein that is regulated by hormones and is involved in lipid metabolism and the displacement of beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors located in brain synapses. DBI is conserved from yeast to mammals, with the most highly conserved domain consisting of seven contiguous residues that constitute the hydrophobic binding site for medium- and long-chain acyl-Coenzyme A esters. Diazepam binding inhibitor is also known to mediate the feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin, in addition to its role as a mediator in corticotropin-depend ent adrenal steroidogenesis.

Suppliers

Company
Product
Description
Supplier Links
Fitzgerald Industries International, Inc.
Acton, MA, USA
DBI Blocking Peptide
33R-6477
DBI Blocking Peptide 33R-6477
A synthetic peptide for use as a blocking control in assays to test for specificity of DBI antibody, catalog no. 70R-2557 Background: DBI is diazepam binding inhibitor. The protein that is regulated by hormones and is involved in lipid metabolism and the displacement of beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors located in brain synapses. DBI is conserved from yeast to mammals, with the most highly conserved domain consisting of seven contiguous residues that constitute the hydrophobic binding site for medium- and long-chain acyl-Coenzyme A esters. Diazepam binding inhibitor is also known to mediate the feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin, in addition to its role as a mediator in corticotropin-depend ent adrenal steroidogenesis.

A synthetic peptide for use as a blocking control in assays to test for specificity of DBI antibody, catalog no. 70R-2557
Background:
DBI is diazepam binding inhibitor. The protein that is regulated by hormones and is involved in lipid metabolism and the displacement of beta-carbolines and benzodiazepines, which modulate signal transduction at type A gamma-aminobutyric acid receptors located in brain synapses. DBI is conserved from yeast to mammals, with the most highly conserved domain consisting of seven contiguous residues that constitute the hydrophobic binding site for medium- and long-chain acyl-Coenzyme A esters. Diazepam binding inhibitor is also known to mediate the feedback regulation of pancreatic secretion and the postprandial release of cholecystokinin, in addition to its role as a mediator in corticotropin-dependent adrenal steroidogenesis.

Supplier's Site

Technical Specifications

  Fitzgerald Industries International, Inc.
Product Category Biological Materials
Product Number 33R-6477
Product Name DBI Blocking Peptide
Unlock Full Specs
to access all available technical data

Similar Products